Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sandoz Group AGXSWX:SDZ +1.41%26 Days Sales Outstanding is 79.91 as of Jun. 2026, which is 6% below its 10-year median of 84.95. GuruFocus rates XSWX:SDZ with a GF Score™ of 26/100 and a GF Value™ of CHF46.92 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 946 Drug Manufacturers companies, Sandoz Group AG ranks worse than 55.07% on this metric.
The historical rank and industry rank for Sandoz Group AG's Days Sales Outstanding or its related term are showing as below:
XSWX:SDZ'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 77.43 Med: 84.95 Max: 91.3
Current: 77.43
During the past 4 years, Sandoz Group AG's highest Days Sales Outstanding was 91.30. The lowest was 77.43. And the median was 84.95.
XSWX:SDZ's Days Sales Outstanding is ranked worse than 55.07% of 946
companies
in the Drug Manufacturers industry
Industry Median: 71.885
vs XSWX:SDZ: 77.43
Sandoz Group AG's Days Sales Outstanding
declined
from Jun. 2025 (82.01) to Jun. 2026 (79.91).
Sandoz Group AG (XSWX:SDZ) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Sandoz Group AG Days Sales Outstanding Related Terms
Sandoz Group AG Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Sandoz Group AG's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:SDZ vs ZTS, UTHR, VTRS: Days Sales Outstanding Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sandoz Group AG Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Sandoz Group AG's Days Sales Outstanding falls into.
Sandoz Group AG Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sandoz Group AG (XSWX:SDZ) has a Days Sales Outstanding of 79.91 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Sandoz Group AG and its competitors. This is near median its historical median of 84.95. Over the past decade, Sandoz Group AG's Days Sales Outstanding has ranged from 77.43 to 91.30. According to the industry distribution chart, Sandoz Group AG ranks #521 out of 946 companies in the Drug Manufacturers industry, placing it in the top 55.1%.
Is Sandoz Group AG's Days Sales Outstanding too high?
Sandoz Group AG's current Days Sales Outstanding of 79.91 is near median its 10-year median of 84.95. Over the past 10 years, this metric has ranged from a low of 77.43 to a high of 91.30. The Drug Manufacturers industry median Days Sales Outstanding is 71.89. Sandoz Group AG's value of 79.91 is 11.2% above this industry median. Based on the distribution chart, Sandoz Group AG ranks #521 out of 946 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sandoz Group AG has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sandoz Group AG's Days Sales Outstanding compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sandoz Group AG ranks #521 out of 946 companies for Days Sales Outstanding. This places Sandoz Group AG in the lower half of its industry. The industry median Days Sales Outstanding is 71.89. Sandoz Group AG's value of 79.91 is 11.2% above this benchmark. Historically, Sandoz Group AG's own Days Sales Outstanding has ranged from 77.43 to 91.30 over the past decade. While the company's 10-year median is 84.95 vs. the industry median of 71.89, Sandoz Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.89, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sandoz Group AG's current Days Sales Outstanding of 79.91 is 11.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Sandoz Group AG and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sandoz Group AG's current Days Sales Outstanding is 79.91, which is near median its own 10-year median of 84.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandoz Group AG stock overvalued right now?
Based on GuruFocus' analysis, Sandoz Group AG (XSWX:SDZ) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF46.92, compared to a current price of CHF68.88 — trading 46.8% above its estimated fair value. The current Days Sales Outstanding is 79.91, which is near median its 10-year median of 84.95 and 11.2% above the Drug Manufacturers industry median of 71.89. Sandoz Group AG's overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Sandoz Group AG (XSWX:SDZ), the current Days Sales Outstanding is 79.91 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sandoz Group AG (XSWX:SDZ) Overvalued in 2026?
Based on GuruFocus' analysis, Sandoz Group AG stock appears to be overvalued.
The current stock price of CHF68.88 is trading 46.8% above its estimated GF Value™ of CHF46.92.
GuruFocus considers Sandoz Group AG to be Significantly Overvalued.
Key valuation signals for XSWX:SDZ:
Days Sales Outstanding: 79.91 (near median its 10-year median of 84.95)
GF Value™: CHF46.92 vs. price of CHF68.88 (46.8% above fair value)
Industry Position: 11.2% above the Drug Manufacturers median (#521 of 946)
No single metric tells the full story. See the XSWX:SDZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
26GF Score
Get the complete analysis for XSWX:SDZ
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:SDZ has been successfully added to your 
